Infliximab for parenchymal neuro-Behçet's syndrome: case series and meta-analysis.

IF 3.4 4区医学 Q2 RHEUMATOLOGY

Clinical and experimental rheumatology Pub Date : 2024-10-01 Epub Date: 2024-05-15 DOI:10.55563/clinexprheumatol/5lnkd4

Xiaoou Wang, Yeling Liu, Yiyuan Ao, Jing Wang, Jinjing Liu, Yan Xu, Wenjie Zheng

{"title":"Infliximab for parenchymal neuro-Behçet's syndrome: case series and meta-analysis.","authors":"Xiaoou Wang, Yeling Liu, Yiyuan Ao, Jing Wang, Jinjing Liu, Yan Xu, Wenjie Zheng","doi":"10.55563/clinexprheumatol/5lnkd4","DOIUrl":null,"url":null,"abstract":"Objectives: This study aims to evaluate the efficacy and safety of infliximab (IFX) in patients with parenchymal neuro-Behçet's syndrome (p-NBS).Methods: We retrospectively analysed eleven p-NBS patients treated with IFX at our institution and combined them with studies from database searches for a meta-analysis. Pooled estimates of clinical response (complete and partial remission) and MRI improvement at months 3, 6, and 12 were calculated.Results: One patient achieved CR and the other ten patients achieved PR at our institution. 8 studies (77 patients) were included in the meta-analysis. At 3, 6, and 12 months, 97% (95%CI 61.9-100%), 89.6% (95%CI 45.9-100%), 100% (95%CI 96.0-100%) of patients showed clinical response and 100% (95%CI 89.7-100%), 89.1% (95% CI 26.3-100%), 99.5% (95% CI 96.0-100%) of patients showed radiological improvement, respectively. Severe adverse events were observed in 7 patients.Conclusions: IFX was effective and relatively safe for p-NBS. Patients should be re-evaluated after 3 months of IFX to determine further therapy.","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"2040-2048"},"PeriodicalIF":3.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/5lnkd4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aims to evaluate the efficacy and safety of infliximab (IFX) in patients with parenchymal neuro-Behçet's syndrome (p-NBS).

Methods: We retrospectively analysed eleven p-NBS patients treated with IFX at our institution and combined them with studies from database searches for a meta-analysis. Pooled estimates of clinical response (complete and partial remission) and MRI improvement at months 3, 6, and 12 were calculated.

Results: One patient achieved CR and the other ten patients achieved PR at our institution. 8 studies (77 patients) were included in the meta-analysis. At 3, 6, and 12 months, 97% (95%CI 61.9-100%), 89.6% (95%CI 45.9-100%), 100% (95%CI 96.0-100%) of patients showed clinical response and 100% (95%CI 89.7-100%), 89.1% (95% CI 26.3-100%), 99.5% (95% CI 96.0-100%) of patients showed radiological improvement, respectively. Severe adverse events were observed in 7 patients.

Conclusions: IFX was effective and relatively safe for p-NBS. Patients should be re-evaluated after 3 months of IFX to determine further therapy.

查看原文本刊更多论文

英夫利西单抗治疗实质性神经-贝赫切特综合征：病例系列和荟萃分析。

研究目的本研究旨在评估英夫利西单抗（IFX）对实质神经-贝赫切特综合征（p-NBS）患者的疗效和安全性：我们回顾性分析了本院接受IFX治疗的11例p-NBS患者，并将其与数据库搜索的研究结果结合起来进行荟萃分析。计算了临床反应（完全缓解和部分缓解）和 MRI 在第 3、6 和 12 个月的改善情况的汇总估计值：在我院，一名患者获得了 CR，另外 10 名患者获得了 PR。8 项研究（77 名患者）被纳入荟萃分析。在3、6和12个月时，分别有97%（95%CI 61.9-100%）、89.6%（95%CI 45.9-100%）、100%（95%CI 96.0-100%）的患者出现临床反应，100%（95%CI 89.7-100%）、89.1%（95%CI 26.3-100%）、99.5%（95%CI 96.0-100%）的患者出现放射学改善。7例患者出现严重不良反应：IFX对p-NBS有效且相对安全。结论：IFX对p-NBS有效且相对安全，患者应在IFX治疗3个月后进行重新评估，以确定进一步的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and experimental rheumatology 医学-风湿病学

CiteScore

6.10

自引率

18.90%

发文量

377

审稿时长

3-6 weeks

期刊介绍： Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.